Autolus Therapeutics (NASDAQ:AUTL) issued its quarterly earnings results on Thursday. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.26, Fidelity Earnings reports. The business had revenue of $0.30 million during the quarter, compared to analyst estimates of $2.00 million.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Shares of NASDAQ:AUTL traded down $0.34 during midday trading on Friday, hitting $12.05. The company’s stock had a trading volume of 35,700 shares, compared to its average volume of 155,734. Autolus Therapeutics has a fifty-two week low of $9.50 and a fifty-two week high of $53.24. The stock’s 50 day simple moving average is $12.51 and its 200 day simple moving average is $15.66. The company has a debt-to-equity ratio of 0.09, a quick ratio of 13.12 and a current ratio of 13.12. The stock has a market capitalization of $573.69 million, a price-to-earnings ratio of -8.49 and a beta of 0.67.
Several brokerages have recently issued reports on AUTL. Needham & Company LLC began coverage on Autolus Therapeutics in a research report on Monday, September 23rd. They issued a “buy” rating and a $26.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $24.00 price target on shares of Autolus Therapeutics in a research report on Thursday, September 12th. ValuEngine raised Autolus Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, William Blair reaffirmed a “buy” rating on shares of Autolus Therapeutics in a research report on Thursday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $33.33.
Autolus Therapeutics Company Profile
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.
Further Reading: What is Depreciation?